SalMar – Q4 2022 Trading update
Consolidated harvest volumes in Q4 2022 are:
Farming Central Norway (1,000 tgw): 32.6
Farming Northern Norway (1,000 tgw): 24.1
Icelandic Salmon (1,000 tgw): 6.0
Total Q4 2022 (1,000 tgw): 62.7
For the full year 2022 consolidated harvest volumes are:
Farming Central Norway (1,000 tgw): 114.1
Farming Northern Norway (1,000 tgw): 63.4
Icelandic Salmon (1,000 tgw): 16.1
Total FY 2022 (1,000 tgw): 193.7
The full Q4 2022 report will be released on 22 February 2023 at 06:30 CET, the following presentation will be available through Norwegian webcast at 08:00 CET and English webcast (recording) at 10:00 CET.
For more information, please contact:
Håkon Husby
Head of Investor Relations
Tel: +47 936 30 449
Email: hakon.husby@salmar.no
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nokia and BT Group sign agreement to drive new 5G monetization opportunities through telco APIs11.12.2023 07:00:00 CET | Press release
Press Release Nokia and BT Group sign agreement to drive new 5G monetization opportunities through telco APIs Memorandum of understanding covers the utilization of Nokia’s Network as Code platform and developer portal with BT Group’s cloud-native network 11 December 2023 Espoo, Finland – Nokia and BT Group today announced an agreement to develop new 5G network monetization opportunities through Nokia’s Network as Code platform with developer portal (platform) and BT Group’s cloud-native network. BT Group, which operates EE – the UK’s best mobile network1 – is, like other communications service providers, looking to Nokia’s growing ecosystem of developer partners to gain access to simplified network capabilities in the form of software code that can be built into applications for enterprise, industrial, and consumer use cases. The Nokia platform helps operators monetize their 5G network assets beyond pure connectivity. It provides application developers with tools such as Software Devel
New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma11.12.2023 07:00:00 CET | Press release
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6 Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, 9-12 December 2023. Based on 32-month and 3-year follow-ups of two pivotal studies for fixed-duration treatments of Columvi® (glofitamab) and Lunsumio® (mosunetuzumab), respectively, data show that remissions were maintained in the majority of patients with heavily pre-treated lymphomas.1,2 Additionally, new early-phase data of novel Columvi or Lunsumio combination regimens support o
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone11.12.2023 01:30:59 CET | Press release
Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone Phase 3 data showed Sarclisa added to carfilzomib, lenalidomide and dexamethasone (KRd) in patients with newly diagnosed, transplant-eligible multiple myeloma resulted in 77% of patients achieving minimal residual disease (MRD) negativity after consolidation therapy, detected with a sensitivity of 10-5MRD negativity rate measured at a sensitivity of 10-6 was 67% for Sarclisa combination therapyResults shared during oral presentation at ASH 2023 plenary scientific session PARIS, December 10, 2023. The Phase 3 trial investigating Sarclisa® (isatuximab) in combination with carfilzomib, lenalidomide and dexamethasone (KRd) showed a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidatio
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)11.12.2023 01:30:00 CET | Press release
APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigue in the majority of patients, with a safety profile consistent with previously reported data1-5 Patients switching from anti-C5s to Fabhalta in the extension period achieved outcomes comparable to the Fabhalta arm in the 24-week randomized controlled period, including transfusion avoidance and near-normal hemoglobin-levels (≥12 g/dL) in the majority of patients1 Fabhalta was recently approved by the FDA for adults with PNH, including for both previously treated and treatment-naive patients6 Basel, December 11, 2023 – Novartis today announced results from the extension period of the pivotal Phase III APPLY-PNH trial of oral monotherapy Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) who h
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia10.12.2023 18:05:00 CET | Press release
Part 5 data reinforces favorable safety and tolerability profile and long-term efficacy results for SerpinPC:Median all-bleed ABR of 1.0, a 96% reduction from prospective baseline No thromboembolic events or treatment-related sustained elevations of D-dimer observedPoster presentation at American Society of Hematology (ASH) Annual meeting Registrational PRESent-2 and PRESent-3 studies of SerpinPC in hemophilia B are ongoing BOSTON and LONDON, Dec. 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia. The data were shared in a poster presentation at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 10, 2023. SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemoph